BioMarin puts $275m upfront on Alesta to secure ALE1, a potential first oral therapy for HPP

On 18 August 2026, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced it had entered into a definitive agreement to acquire Alesta Therapeutics to gain Alesta's lead clinical-stage asset, ALE1.¹ BioMarin will pay $275 million upfront, plus up to $215 million in subsequent payments upon achievement of certain development and regulatory milestones. The transaction has been approved by the boards of both companies and is expected to be completed this quarter (Q3 2026), subject to customary closing conditions.

ALE1 is an orally active small molecule for the potential treatment of hypophosphatasia (HPP), a rare genetic bone disease caused by mutations in the ALPL gene. The candidate is being evaluated in an ongoing Phase 1/2a clinical trial assessing safety, tolerability and pharmacokinetics/pharmacodynamics in healthy volunteers and adults with HPP, and has the potential to be the first oral therapy for HPP.¹ Following close, the program will become part of BioMarin's Skeletal Conditions Business Unit.

Structure matters as much as price. Immediately prior to close, Alesta will spin out all non-ALE1 assets to a new entity, and former Alesta employees will transfer to that spinout. As a result, no Alesta employees become employees of BioMarin in connection with the transaction.¹ BioMarin intends to fund the deal with cash on hand, expects updated full-year 2026 guidance after closing, and describes the transaction (excluding the upfront) as modestly dilutive to 2026 financial results.

The announcement lands in an active August 2026 M&A window that also includes Munich Re's $575 million At-Bay agreement and Bending Spoons' $1.285 billion Airtable transaction. BioMarin's deal is a different species of strategic bet: a public rare-disease company paying cash for a single clinical program with a pre-close perimeter clean-up, not a platform roll-up or carrier-scale InsurSec consolidation.

BioMarin disclosed a clear cash-and-milestones package and an unusual people-and-assets perimeter. The primary release does not publish equity value alternatives, earn-out schedules beyond the milestone cap, peak sales forecasts, or EV/sales multiples.¹ Acquiry therefore anchors on disclosed consideration only.

What we know from primary sources:

• Upfront: $275 million
• Milestones: up to $215 million (development and regulatory)
• Total potential consideration: up to $490 million ($275M + up to $215M)
• Asset: ALE1 (oral small molecule for HPP; Phase 1/2a ongoing)
• Structure: Non-ALE1 assets spin out before close; Alesta employees transfer to spinout
• Employment: No Alesta employees join BioMarin
• Funding: Cash on hand; modestly dilutive to 2026 excluding upfront; updated FY2026 guidance post-close
• Timing: Expected close this quarter (Q3 2026), customary conditions
• Advisors: Morgan Stanley and Jones Day (BioMarin); J.P. Morgan, Goodwin Procter, NautaDutilh (Alesta)

Rare-disease strategics face a recurring problem: commercial franchises age, injectable standards of care leave adherence and convenience gaps, and early clinical pipeline slots are expensive to fill through internal discovery alone. ALE1 is BioMarin's answer to that problem in hypophosphatasia: an oral small molecule aimed at the central disease metabolite, inorganic pyrophosphate (PPi), with the potential to address skeletal and broader HPP manifestations through systemic correction of disease biology.¹

Alexander Hardy, BioMarin's President and Chief Executive Officer, framed the strategic fit in portfolio language rather than near-term sales theater: ALE1 brings "a potential oral alternative to the injectable therapies available today" and "meaningfully strengthen[s] our early-stage clinical pipeline," while letting BioMarin "compete in larger rare disease markets" with an asset that could reach its "largest addressable patient population."¹ That is a growth thesis built on unmet need and modality shift, not a disclosed peak-sales number.

Biotech M&A in 2026 is not a single market. Platform software deals price recurring revenue; carrier InsurSec deals price premium books; clinical rare-disease deals price probability-weighted pipeline optionality. BioMarin's Alesta transaction belongs in the third bucket. Readers should not import EV/ARR logic from Airtable or EV/GWP logic from At-Bay into a Phase 1/2a oral HPP candidate.

What the Alesta deal does re-price is asset perimeter design. By forcing a pre-close spinout of non-ALE1 assets and transferring employees to that spinout, BioMarin shows how strategics can buy a clinical program without absorbing an entire operating company. That structure will influence term sheets elsewhere in rare disease: expect more "asset plus residual NewCo" conversations when buyers want one molecule and sellers want continuity for everything else.

Near-term execution has three tracks: closing mechanics, spinout completion, and clinical continuity for ALE1. BioMarin expects the acquisition to complete this quarter, subject to customary closing conditions.¹ The release does not enumerate antitrust jurisdictions or Form filings in detail, so the public checkpoint is simply whether the companies confirm close inside Q3 2026.

The spinout is a closing condition in practical terms even if described as a pre-close step. Alesta must move non-ALE1 assets into a new entity and transfer employees before BioMarin takes ALE1. Any delay in corporate separation, IP assignment, or employment transfer can push close even when cash and board approvals are ready. Counterparties watching this deal should treat spinout readiness as a leading indicator.

After close, ALE1 joins BioMarin's Skeletal Conditions Business Unit. That is the integration authority for development planning. Key milestones Acquiry will track: confirmation of close, updated FY2026 guidance, Phase 1/2a progress disclosures, and any later milestone triggers that convert the contingent $215 million into cash outflow. Until those primary sources publish, contingent consideration remains a ceiling, not a schedule.

For BioMarin equity holders, the modest-dilution comment (excluding upfront) and cash-funding plan reduce financing drama relative to equity-heavy biotech deals. The open question is opportunity cost: how ALE1 competes for internal capital against other pipeline priorities once it sits inside the skeletal franchise. Earnings commentary and guidance language after close will be the first place that trade-off becomes visible.

For Alesta's residual stakeholders in the spinout, the transaction is both an exit on ALE1 economics and a reset of the remaining portfolio. The release praises Alesta's scientific and drug-development capabilities while making clear those employees do not move to BioMarin.¹ Continuity of the residual company, not BioMarin retention packages, is the talent story to watch.

Acquiry will update this report when primary sources publish closing confirmation, guidance revisions, clinical updates, or milestone disclosures. Continuous reporting is core to Deal Intelligence: transaction pages are living documents, not static press summaries.

Acquiry's read is that BioMarin paid for a ring-fenced clinical option on oral HPP, not for a biotech platform story detached from ALE1. The combination of $275 million upfront, a capped milestone package, cash funding, a near-term close, and a mandatory non-ALE1 spinout is a coherent strategic design: buy the asset, leave the residual company behind, and seat the program in an existing skeletal business unit.

Three structural forces make this deal instructive beyond the headline cash. First, buyer type: BioMarin is a public rare-disease operator with nine commercial therapies and permanent franchise incentives. That changes negotiation dynamics versus a financial sponsor. Milestone definitions tied to development and regulatory events fit a strategic that can run Phase programs; they are less about quick margin expansion and more about clinical progression.

Second, perimeter engineering. Acqui-hires are common in software. This deal is the opposite: an acqui-asset with an explicit no-employee transfer to the buyer. Founders and boards structuring rare-disease exits should study whether a spinout improves bid clarity. Sometimes the cleanest way to maximize ALE1-like value is to stop forcing buyers to underwrite unrelated programs and payroll.

Third, disclosure discipline. The primary release is rich on structure and silent on peak sales. That silence is a feature of responsible clinical-stage communication, not a gap Acquiry should fill with invented forecasts. Deal Intelligence exists to cite what was said, label what is interpretation, and refuse fabricated multiples. The comparable set on this page therefore points to sibling August 2026 reports (Munich Re × At-Bay, Bending Spoons × Airtable) for M&A tempo, not for biotech revenue math.

For shareholders exploring a sale of a clinical rare-disease asset, the BioMarin × Alesta package is a useful term-sheet reference: upfront cash large enough to clear a process, milestones capped and labeled, funding certainty from a public balance sheet, and a structural answer for residual IP and people. It is not a template for inventing commercial peaks. It is a template for selling what a strategic can actually underwrite.

Regulatory and clinical risk remain real. Phase 1/2a status means safety, tolerability, and PK/PD are still being established in healthy volunteers and adults with HPP. Closing this quarter does not de-risk the molecule. It only transfers that risk to BioMarin's skeletal franchise under a defined cash-and-milestones envelope.

If you are evaluating a sale of a clinical-stage rare-disease program, this transaction is a useful comp for structure and buyer mapping. Acquiry tracks strategic mandates through our Deal Intelligence programme and sell-side advisory work via the Acquisitions hub.